SCHEMBL5339539

SCHEMBL5339539

COc1ccc(N(C)c2ncnc3ccsc23)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.53
DYRK1B Q9Y463 1/20 0.53
CSF1R P07333 13/20 0.50
EGFR P00533 13/20 0.50
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48
TUBB6 Q9BUF5 1/20 0.48
TUBB2B Q9BVA1 1/20 0.48
TUBB1 Q9H4B7 1/20 0.48
PDGFRB P09619 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579136 0.85 TUBB4A (0.64) DYRK1ADYRK1BCSF1REGFRTUBB4A
SCHEMBL5579199 0.84 TUBB4A (0.50) DYRK1ADYRK1BCSF1REGFRTUBB4A
SCHEMBL5579181 0.84 CSF1R (0.52) CSF1REGFRTUBB4ATUBBTUBA3C
SCHEMBL5315202 0.84 TUBB4A (0.44) DYRK1ADYRK1BCSF1REGFRTUBB4A
SCHEMBL18540829 0.83 TUBB3 (0.59) CSF1REGFRTUBB4ATUBBTUBA3C
SCHEMBL5579165 0.78 CSF1R (0.43) CSF1REGFRTUBB4ATUBBTUBA3C
SCHEMBL2259237 0.76 CSF1R (0.64) CSF1REGFRPDGFRBPDGFRAKDR
SCHEMBL5579169 0.75 TUBB4A (0.44) DYRK1ADYRK1BCSF1REGFRTUBB4A
SCHEMBL18540831 0.75 EGFR (0.49) DYRK1ADYRK1BCSF1REGFRTUBB4A
Hydrochloric Acid SCHEMBL5579369 0.74 TUBB4A (0.43) DYRK1ADYRK1BCSF1REGFRTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-09-13 US claimed
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-09-13 US disclosed
WO-2007056214-A2 N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF CYTOVIA, INC (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP10, CASP4, CASP3 DYRK1A 4369/4885DYRK1B 4566/4885CSF1R 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.